Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

Lloyd-Jones, 2010, Heart disease and stroke statistics—2010 update: a report from the American Heart Association, Circulation, 121, 46 Wolf, 1991, Atrial fibrillation as an independent risk factor for stroke: the Framingham Study, Stroke, 22, 983, 10.1161/01.STR.22.8.983 1994, Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials, Arch Intern Med, 154, 1449, 10.1001/archinte.1994.00420130036007 Hart, 2007, Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation, Ann Intern Med, 146, 857, 10.7326/0003-4819-146-12-200706190-00007 De Caterina, 2013, Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis—Task Force on Anticoagulants in Heart Disease, Thromb Haemost, 110, 1087, 10.1160/TH13-06-0443 De Caterina, 2013, General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis—Task Force on Anticoagulants in Heart Disease, Thromb Haemost, 109, 569, 10.1160/TH12-10-0772 Holbrook, 2005, Systematic overview of warfarin and its drug and food interactions, Arch Intern Med, 165, 1095, 10.1001/archinte.165.10.1095 Gallego, 2013, Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation, Thromb Haemost, 110, 1189, 10.1160/TH13-07-0556 Apostolakis, 2013, Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score, Chest, 144, 1555, 10.1378/chest.13-0054 Lip, 2013, Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?, Eur Heart J, 34, 1041, 10.1093/eurheartj/ehs435 Lip, 2014, Antagonist oral anticoagulants: an appeal for consensus on terminology, Chest, 145, 1177, 10.1378/chest.13-2951 De Caterina, 2012, New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working group on thrombosis—Task Force on anticoagulants in heart disease position Paper, J Am Coll Cardiol, 59, 1413, 10.1016/j.jacc.2012.02.008 Huisman, 2012, Dabigatranetexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice, Thromb Haemost, 107, 838, 10.1160/TH11-10-0718 Pengo, 2011, Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation, Thromb Haemost, 106, 868, 10.1160/TH11-05-0358 Turpie, 2012, Management consensus guidance for the use of rivaroxaban—an oral, direct factor Xa inhibitor, Thromb Haemost, 108, 876, 10.1160/TH12-03-0209 Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638 Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 Giugliano, 2013, Once-daily edoxaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 369, 2093, 10.1056/NEJMoa1310907 Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 O’Neil, 2013, Do open label blinded outcome studies of novel anticoagulants versus warfarin have equivalent validity to those carried out under double-blind conditions?, Thromb Haemost, 109, 497, 10.1160/TH12-10-0715 Connolly, 2010, Newly identified events in the RE-LY trial, N Engl J Med, 363, 1875, 10.1056/NEJMc1007378 Camm, 2012, 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association, Eur Heart J, 33, 2719, 10.1093/eurheartj/ehs253 Manzano-Fernández, 2012, Mild kidney disease as a risk factor for major bleeding in patients with atrial fibrillation undergoing percutaneous coronary stenting, Thromb Haemost, 107, 51, 10.1160/TH11-08-0524 Roldán, 2013, Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?, Thromb Haemost, 109, 956, 10.1160/TH13-01-0054 Banerjee, 2013, A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project, Chest Banerjee, 2013, Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project, J Am Coll Cardiol, 61, 2079, 10.1016/j.jacc.2013.02.035 Roldán, 2013, Renal impairment in a “real-life” cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding), Am J Cardiol, 111, 1159, 10.1016/j.amjcard.2012.12.045 Eikelboom, 2011, Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-term anticoagulant therapY (RE-LY) trial, Circulation, 123, 2363, 10.1161/CIRCULATIONAHA.110.004747 Legrand, 2011, The use of dabigatran in elderly patients, Arch Intern Med, 171, 1285, 10.1001/archinternmed.2011.314 Hijazi, 2014, Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY trial analysis, Circulation, 129, 961, 10.1161/CIRCULATIONAHA.113.003628 Hohnloser, 2012, Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial, Eur Heart J, 33, 2821, 10.1093/eurheartj/ehs274 Go, 2001, Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study, J Am Med Assoc, 285, 2370, 10.1001/jama.285.18.2370 Mant, 2007, Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial, Lancet, 370, 493, 10.1016/S0140-6736(07)61233-1 Marinigh, 2010, Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis, J Am Coll Cardiol, 56, 827, 10.1016/j.jacc.2010.05.028 Gurwitz, 2003, Incidence and preventability of adverse drug events among older persons in the ambulatory setting, J Am Med Assoc, 289, 1107, 10.1001/jama.289.9.1107 Goto, 2011, Heart Asia, 3, 93 Shen, 2007, Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation, J Am Coll Cardiol, 50, 309, 10.1016/j.jacc.2007.01.098 Suarez, 2012, International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation, Am Heart J, 163, 804, 10.1016/j.ahj.2012.02.008 Chiang, 2014, Stroke prevention in atrial fibrillation: an Asian perspective, Thromb Haemost, 111, 789, 10.1160/TH13-11-0948 Hori, 2013, Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation, Stroke, 44, 1891, 10.1161/STROKEAHA.113.000990 Goto, 2013, Efficacy and safety of apixaban compared with warfarin for stroke prevention in atrial fibrillation in East Asia, Eur Heart J, 34, 1039, 10.1093/eurheartj/eht310.P5613 Guo, 2013, Sequential changes in renal function and the risk of stroke and death in patients with atrial fibrillation, Int J Cardiol, 168, 4678, 10.1016/j.ijcard.2013.07.179 Bernard, 2013, Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation, Thromb Haemost, 110, 560, 10.1160/TH13-04-0351 Azoulay, 2013, The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation, Thromb Haemost, 109, 431, 10.1160/TH12-08-0542 Park, 2010, Duration of dual antiplatelet therapy after implantation of drug-eluting stents, N Engl J Med, 362, 1374, 10.1056/NEJMoa1001266 Mega, 2012, Rivaroxaban in patients with a recent acute coronary syndrome, N Engl J Med, 366, 9, 10.1056/NEJMoa1112277 Alexander, 2011, Apixaban with antiplatelet therapy after acute coronary syndrome, N Engl J Med, 365, 699, 10.1056/NEJMoa1105819 Lane DA, Barker RV, Lip GYH. Best practice for atrial fibrillation education. Curr Pharm Des 2014 (in press). Lane, 2014, Patient’s values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation, Thromb Haemost, 111, 381, 10.1160/TH14-01-0063 Lahaye, 2013, Evaluation of patients’ attitudes towards stroke prevention and bleeding risk in atrial fibrillation, Thromb Haemost, 111, 465 Larsen, 2013, Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study, J Am Coll Cardiol, 61, 2264, 10.1016/j.jacc.2013.03.020 Larsen, 2013, Myocardial ischemic events in “real world” patients with atrial fibrillation treated with dabigatran or warfarin, Am J Med, 01073 Sørensen, 2013, Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study, Br Med J Open, 3 Lip, 2013, Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database, Thromb Haemost, 111, 933 Pisters, 2013, Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey, Thromb Haemost, 109, 328, 10.1160/TH12-08-0539 Banerjee, 2012, Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study, Thromb Haemost, 107, 584, 10.1160/TH11-11-0784